IPSC Century Therapeutics, Inc.
USHealthcareAs of 2026-07-10 15:36
Why IPSC matters now
Century Therapeutics, Inc. (IPSC) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.25 with -2.81% on the session and $194.3M in market capitalization; recent performance reads 1-month +8.02% and YTD +130.20%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-21.6M, and EPS of $-0.25. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -48.4%.
The latest indexable market news headline is "Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes Carr Douglas filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.75
P/S
0.00
EV/EBITDA
-2.17
DCF Value
$2.84
FCF Yield
-48.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-53.2%
ROA
-33.0%
ROIC
-36.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-21.6M | $-0.25 |
| Q4 2025 | $0.00 | $-19.2M | $-0.22 |
| FY 2025 | $109.2M | $-9.6M | $-0.11 |
| Q3 2025 | $0.00 | $-34.4M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$2.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.57
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.